| Autor: |
Sidoroff M; Hospital for Children and Adolescents, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. marianne.sidoroff@helsinki.fi, Kolho KL |
| Jazyk: |
angličtina |
| Zdroj: |
Annals of medicine [Ann Med] 2012 Sep; Vol. 44 (6), pp. 578-87. Date of Electronic Publication: 2011 Oct 13. |
| DOI: |
10.3109/07853890.2011.590521 |
| Abstrakt: |
Glucocorticoid therapy is used in the treatment of moderate to severe inflammatory bowel disease (IBD). However, IBD patients display varying degrees of glucocorticoid sensitivity: some respond rapidly to the given treatment, whereas others show no response, or develop steroid therapy-related side-effects. At present, we cannot foresee whether the patient will benefit from the administered glucocorticoids or not. During the past 10 years, numerous attempts have been made to provide the means to identify and predict steroid therapy-sensitive patients in advance. This would be vital to avoid unnecessary glucocorticoid exposure in patients that do not respond to treatment with steroids. Here we provide a concise review of recent developments regarding the molecular basis of glucocorticoid sensitivity in IBD patients and the methods employed to assess it. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
